

# Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers

NCT07433556

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Il-Yang Pharm. Co., Ltd.
Enrollment	86 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Healthy adult volunteers aged e 19 and d 50 years at screening
- Body weight e 50.0 kg to d 90.0 kg and body mass index (BMI) of e 18.5 kg/m<sup>2</sup> to d 29.9 kg/m<sup>2</sup> at screening
- Volunteers who were fully informed of and completely understood this study, voluntarily agreed to participate, and provided written consent to comply with the precautions

### Exclusion (5)

- Current or history of clinically significant disease of hepatobiliary (severe hepatic impairment, viral hepatitis, etc.), renal (severe renal impairment, etc.), nervous, immune, respiratory, gastrointestinal, endocrine, hemato-oncologic, cardiovascular (heart failure, torsades de pointes, etc.), urinary, or psychiatric (mood disorder, obsessive compulsory disorder, etc.) system or sexual dysfunctions
- H. pylori eradication treatment within 6 months or positive result for H. pylori at screening
- Hypersensitivity or history of clinically significant hypersensitivity to PPIs, P-CABs, and other drugs (aspirin, antibiotics, etc.)
- A positive result in serology (hepatitis B tests, hepatitis C tests, human immunodeficiency virus [HIV] tests, or syphilis tests)
- History of drug abuse or positive results for drug abuse in the urine drug screen

## Locations (1 total)

---

Seoul National University Hospital, Seoul, South Korea